-

BrainCheck Opens New York City Office to Support Northeast Growth

AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--BrainCheck, a leading digital cognitive assessment and care platform, today announced the opening of its new East Coast office at 325 Hudson Street in New York City.

“Establishing a dedicated presence in the Northeast allows us to better support our customers, deepen partnerships with leading institutions, and accelerate growth in a region that is shaping the future of cognitive care.”

Share

The New York office will serve as BrainCheck’s Northeast hub, supporting growing demand from health systems, academic medical centers, specialty practices, and research organizations across the region. The expansion reflects continued momentum as healthcare organizations increasingly adopt digital tools for objective cognitive assessment and longitudinal cognitive care.

BrainCheck is currently used by leading clinical and academic institutions nationwide, including Cleveland Clinic, Stanford University, MD Anderson Cancer Center, Mount Sinai Health System, UPMC, the University of Texas at Austin, Oregon Health & Science University, the University of Colorado Anschutz Medical Campus, Springfield Clinic, and Dent Neurologic Institute, among many others. These partnerships span neurology, psychiatry, primary care, and research settings.

“New York is a critical center for healthcare delivery, academic medicine, and life sciences,” said Chris Loughlin, CEO of BrainCheck. “Establishing a dedicated presence in the Northeast allows us to better support our customers, deepen partnerships with leading institutions, and accelerate growth in a region that is shaping the future of cognitive care.”

BrainCheck’s platform includes its FDA Class II digital cognitive assessment, BrainCheck Assess™, along with more than 20 validated cognitive and behavioral screeners and digital care planning tools. The platform is designed to support early detection, standardized assessment, and ongoing monitoring of cognitive health across diverse care environments.

The New York office complements BrainCheck’s headquarters in Austin, Texas, and aligns with the company’s broader strategy to expand its national footprint while remaining closely connected to customers and clinical partners.

For more information, visit www.braincheck.com.

About BrainCheck

BrainCheck is an FDA Class II–cleared digital platform for cognitive assessment and care, used by over 500 healthcare organizations nationwide, including Bon Secours, UPMC, and Springfield Clinic. Clinicians use BrainCheck’s validated screeners and care planning tools to create tailored protocols, completing more than 400,000 cognitive assessments to date. BrainCheck is not intended for use as a stand-alone diagnostic tool.

Contacts

Media Contact
Kate Smith
Senior Marketing Specialist
BrainCheck Inc
kate.smith@braincheck.com

BrainCheck


Release Versions

Contacts

Media Contact
Kate Smith
Senior Marketing Specialist
BrainCheck Inc
kate.smith@braincheck.com

Social Media Profiles
More News From BrainCheck

Peer-Reviewed Study Design Paper Published for PREDICTOM Alzheimer's Screening Initiative Featuring BrainCheck

AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--BrainCheck Inc., a cognitive workflow platform, today highlighted the publication of a peer-reviewed study design paper for PREDICTOM — the large-scale European Alzheimer's early detection initiative in which BrainCheck Assess is serving as a cognitive assessment tool. The paper, published in The Journal of Prevention of Alzheimer's Disease, details the full protocol for a novel AI-driven screening platform designed to bring Alzheimer's diagnostics int...

New Peer-Reviewed Study Using BrainCheck Identifies Four Distinct Cognitive Trajectories in Patients Hospitalized for COVID-19

AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--BrainCheck Inc., a cognitive workflow platform, today highlighted the publication of a peer-reviewed longitudinal study conducted at UTHealth Houston that used BrainCheck to track cognitive outcomes in patients hospitalized for COVID-19 over a 36-month period. The study, published in The Journal of Neuropsychiatry and Clinical Neurosciences, represents one of the largest and longest-running evaluations of cognitive outcomes following COVID-19 hospitali...

Dr. Stephen Bekanich Joins BrainCheck as Chief Medical Officer

AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--BrainCheck Inc., a digital platform for cognitive assessment and care, today announced that Stephen Bekanich, M.D., has joined the company as Chief Medical Officer. In this role, Dr. Bekanich will lead BrainCheck’s clinical strategy and help expand its value-based and collaborative care initiatives as the company continues to scale nationally. Dr. Bekanich brings decades of experience in geriatric medicine, palliative care, accountable care organizatio...
Back to Newsroom